Almirall partners with Ablexis and AlivaMab Discovery Services to accelerate its development efforts for innovative treatment options for patients suffering from severe skin diseases

Almirall partners with Ablexis and AlivaMab Discovery Services to accelerate its development efforts for innovative treatment options for patients suffering from severe skin diseases

  • Through this license agreement with Ablexis, Almirall is granted rights to use the AlivaMab® Mouse technology for research, development, and commercialisation of antibodies
  • AlivaMab Mouse offers state-of-the-art transgenic mouse platforms delivering highdiversity human therapeutic antibodies
  • Almirall will partner with AlivaMab Discovery Services (ADS) to perform the drug discovery research, leveraging the ADS team’s expertise in antibody drug discovery and engineering

(PRESS RELEASE) BARCELONA, Spain / SAN DIEGO, Calif., United States, 31-Jan-2022 — /EuropaWire/ — Almirall, S.A. (BME: ALM), a Spanish pharmaceutical company with focus on skin health, has announced it signed a multi-target licensing agreement with Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, and a research collaboration with AlivaMab Discovery Services, LLC, a leader in the discovery and engineering of antibody therapeutics.

Under the terms of the license, Almirall is granted non-exclusive rights to use Ablexis’ AlivaMab Mouse technology for the discovery, development, and commercialization of innovative antibody drugs.

In addition, Almirall will collaborate with AlivaMab Discovery Services to conduct the research, leveraging ADS’ expertise in antibody drug discovery and engineering using the AlivaMab Mouse technology, a state-of-art platform for the generation of human therapeutic antibodies.

“These agreements are in line with Almirall’s vision to develop innovative treatment options for patients suffering from severe skin diseases. AlivaMab Discovery Services’ profound know-how in antibody discovery and engineering together with Almirall’s expertise in dermatology will strongly accelerate the development of differentiated treatments to help patients get closer to their goal of leading a healthy life,” stated Dr. Thomas Huber, Research Director at Almirall. “The agreements highlight the company’s commitment to early biologics discovery to provide the best solutions to skin conditions through novel science.”

“We are pleased that Almirall has selected the AlivaMab Mouse technology as a key platform for its antibody drug discovery,” said Larry Green, Chief Executive Officer, Ablexis, LLC. “Together with the talented and highly experienced team of antibody drug hunters at Ablexis’ sister company, AlivaMab Discovery Services, we are increasingly recognized by partners with real experience in antibody drug discovery and development.”

“Almirall joins our rapidly expanding list of high-quality partners that leverage the discovery, engineering and developability assessment capabilities of ADS, especially for challenging targets, functional design goals and advanced modalities,” said Justin Mika, Chief Executive Officer at AlivaMab Discovery Services. “Our partners appreciate how our team’s expertise, combined with the proven AlivaMab Mouse platform, significantly improves the probability of success and shortens timelines in discovery and development. We look forward to supporting Almirall’s efforts to help patients with dermatological conditions.”

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 78-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.

For more information, please visit

Media contact:
T+ 34 932 913 000

SOURCE: Almirall, S.A.



Comments are closed.